Skip to main content

Healthcare / Neonatal Care

Automated nitric oxide therapy system: Connected iNO delivery for NICU patients

Development of an automated inhaled nitric oxide (iNO) therapy system for NICUs treating newborns with persistent pulmonary hypertension, with design documentation structured to IEC 62304 (Class C) and ISO 13485 expectations. It combines precise gas delivery, real-time NO/NO2 monitoring, cloud connectivity for remote oversight and layered safety interlocks, with a BOM-based estimate of a device cost about 60% below imported iNO delivery systems.

What we did: We designed the gas-delivery control electronics and safety-critical PCB, the IEC 62304 Class C firmware with dual-processor safety architecture, the alarm system and the cloud monitoring platform, and prepared the 510(k) and CE technical documentation.

Medical equipment manufacturer, India20 months

Published Last reviewed:

IEC 62304
Class C firmware design
±10%
Dosing accuracy (or ±0.5 ppm, whichever is greater)
Design target
60%
Lower device cost vs imported iNO systems (BOM estimate)
Design target
4hr
UPS backup + auto cylinder failover
Design target
Illustrative photo: a medical gas delivery unit on a cart beside a neonatal incubatorIllustrative image

The challenge

Newborns with Persistent Pulmonary Hypertension of the Newborn (PPHN) require precise inhaled Nitric Oxide therapy, but existing systems are prohibitively expensive and lack remote monitoring capabilities. An affordable, connected solution was needed for NICUs in emerging markets.

Prohibitive treatment costs

Traditional iNO therapy systems cost $15,000-$25,000 per patient treatment course. This limits access in developing countries where PPHN mortality is highest.

Impact: Limits treatment accessClient-reported baseline

Precise dosing requirements

iNO requires extremely precise delivery (1-80 ppm) as both under-dosing (ineffective) and over-dosing (toxic NO2 formation) are dangerous for fragile newborns.

Impact: Life-critical precisionClient-reported baseline

Continuous monitoring need

NO2 and methemoglobin levels must be continuously monitored. Manual monitoring is labor-intensive and prone to gaps in coverage.

Impact: 24/7 vigilance requiredClient-reported baseline

Remote NICU challenges

Many NICUs lack specialist availability 24/7. Remote expert consultation and monitoring was essential for safe therapy management.

Impact: Limited expertise accessClient-reported baseline

Impact figures describe the situation before the project, as the client reported it to us; we did not measure them.

Our solution

We developed a fully automated iNO delivery system with precise gas mixing, real-time monitoring, cloud connectivity for remote specialist oversight, and safety interlocks — engineered for the FDA 510(k) and CE pathways, with a BOM-based estimate of a device cost about 60% below imported iNO delivery systems.

System architecture

Complete iNO therapy ecosystem from gas delivery to cloud monitoring.

Delivery system

  • Precision NO/N2 gas blending
  • Mass flow controllers (0.1 LPM resolution)
  • Electrochemical NO/NO2 sensors
  • Integration with ventilator circuits
  • Cylinder pressure monitoring
  • Automatic cylinder switchover

Monitoring unit

  • Real-time NO concentration display
  • NO2 level monitoring with alarms
  • SpO2 integration capability
  • Methemoglobin tracking prompts
  • Treatment logging and trending
  • Touch-screen operator interface

Connected platform

  • Cloud-based therapy monitoring
  • Remote specialist consultation
  • Multi-NICU dashboard
  • Treatment protocol management
  • Automatic adverse event reporting
  • Predictive maintenance alerts

Custom hardware design

MCU
STM32F7 with separate safety processor
Flow Control
Mass flow controllers (±1%)
NO Sensor
Electrochemical (0-100 ppm)
NO2 Sensor
Electrochemical (0-10 ppm)
Display
7" Medical-grade LCD
Connectivity
WiFi + Ethernet + 4G backup
Power
Medical-grade PSU + 4hr UPS
Enclosure
IP54; designed to IEC 60601-1

Safety-critical firmware (IEC 62304 Class C)

  • Dual-processor architecture with safety processor
  • Watchdog supervision with safe-state fallback
  • Real-time NO/NO2 PID control loop (100 Hz)
  • Alarm management with priority escalation
  • Comprehensive event logging (1-year storage)
  • Secure OTA updates with rollback capability
  • Self-test routines on startup and continuously
  • Audit trail designed to FDA 21 CFR Part 11

Implementation timeline

Phase 1: Requirements & architecture

10 weeks
  • Clinical requirements with neonatologists
  • Regulatory strategy and predicate analysis
  • FMEA and risk management planning
  • System architecture and safety design

Phase 2: Gas delivery system

16 weeks
  • Precision flow control design
  • Gas mixing chamber optimization
  • Sensor integration and calibration
  • Pneumatic safety system design

Phase 3: Electronics & firmware

18 weeks
  • Safety-critical PCB design
  • IEC 62304 Class C firmware development
  • Alarm system implementation
  • Dual-processor safety architecture

Phase 4: Software platform

14 weeks
  • Cloud monitoring platform
  • Mobile app for remote access
  • EMR integration module
  • Cybersecurity implementation

Phase 5: Verification & validation

14 weeks
  • IEC 60601-1 pre-compliance testing (formal testing by the client at an accredited lab)
  • Gas delivery accuracy validation
  • Clinical simulation testing
  • Biocompatibility assessment

Phase 6: Submission package preparation

8 weeks
  • 510(k) submission compilation
  • Pre-submission response readiness
  • CE technical file preparation
  • Manufacturing validation

Results & impact

The automated iNO therapy system was engineered to improve access to this treatment, with a BOM-based device cost estimate about 60% below imported iNO delivery systems and a connected platform designed to enable remote expert oversight for NICUs lacking specialized staff. All performance figures below are design targets; the device is pre-submission and has no clinical outcome data. CDSCO licensing under the Medical Devices Rules, 2017 (in the risk class CDSCO assigns) is the client's step, as are the FDA and CE filings.

How to read the labels: Design target = an engineering target, not a field measurement; Client-reported baseline = the client's own figure for the situation before the project; we did not measure it. Figures without a label are specifications or project scope.

Dosing accuracy

Design target

±0.5 ppm or ±10%

Of the set NO concentration, whichever is greater; 1-80 ppm range

Device cost reduction

Design target

60%

vs imported iNO delivery systems (BOM-based estimate)

Response time

Design target

< 30 sec

Gas delivery to set point

Development timeline

18 months

Requirements to submission-ready package

Technologies used

  • STM32F7
  • Mass Flow Controllers
  • Electrochemical Sensors
  • IEC 62304
  • React
  • Node.js
  • AWS IoT Core
  • PostgreSQL
  • HL7 FHIR
  • MQTT/TLS

Related case studies

Related services, industries and guides